https://doi.org/10.4081/monaldi.2026.4040
The effect of azelastine on basal forced expiratory volume in one second in asthmatics: a systematic review and meta-analysis
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Accepted: 14 October 2026
Published: 21 October 2026
Nearly 5 to 10% of asthmatics show a problematic drug tachyphylaxis, featuring the need for new therapies. Bitter taste receptors (TAS2Rs) are expressed in the airway tract, and their activation leads to multiple antiasthma effects. Azelastine, an antihistaminic drug with a strong bitter taste, is used to treat allergic rhinitis but is frequently prescribed for asthma. The present study aims to evaluate the bronchodilator effect of azelastine in asthmatic patients. We searched PubMed, the Cochrane Library, and Scopus databases from inception to April 1, 2026. Studies investigating the effect of azelastine on baseline forced expiratory volume in one second (FEV1) of asthmatic patients, compared to a placebo, were included. Mean differences between the two arms were calculated using a random effects model. The systematic search retrieved 145 articles, of which 8 met the inclusion criteria. Azelastine improved FEV1 by 7.57% compared to placebo (p<0.001). The heterogeneity was low (I2=0%), and the overall methodological quality of the selected studies was high, except in four studies, where a risk of bias was observed due to deviations from the intended intervention. Meta-regression analysis showed no significant impact of age, sex ratio, and baseline FEV1 on the global effect size (p>0.05). Azelastine treatment improves FEV1 in asthmatic patients. These results support the previously reported bronchodilator benefits of azelastine through TAS2Rs activation. However, more clinical studies are still needed to explore the therapeutic potential of TAS2R-targeted treatments in asthma.
Downloads
NHLBI. Section 2, definition, pathophysiology and pathogenesis of asthma, and natural history of asthma. In: Expert panel report 3: guidelines for the diagnosis and management of asthma. Bethesda, MD, USA: National Heart, Lung, and Blood Institute (US); 2007.
Dubin S, Patak P, Jung D. Update on asthma management guidelines. Mo Med 2024;121:364-7.
Kamada AK, Leung DY, Szefler SJ. Steroid resistance in asthma: our current understanding. Pediatr Pulmonol 1992;14:180-6. DOI: https://doi.org/10.1002/ppul.1950140307
De Filippo M, Clark E, Fillard A, et al. Oral corticosteroids and asthma in children: Practical considerations. Pediatr Allergy Immunol 2020;31:43-5. DOI: https://doi.org/10.1111/pai.13151
Marques L, Vale N. Salbutamol in the management of asthma: a review. Int J Mol Sci 2022;23:14207. DOI: https://doi.org/10.3390/ijms232214207
Global Initiative for Asthma. GINA report 2024. Available from: https://ginasthma.org/2024-report/.
Jeruzal-Świątecka J, Fendler W, Pietruszewska W. Clinical role of extraoral bitter taste receptors. Int J Mol Sci 2020;21:5156. DOI: https://doi.org/10.3390/ijms21145156
Deshpande DA, Wang WCH, McIlmoyle EL, et al. Bitter taste receptors on airway smooth muscle bronchodilate by localized calcium signaling and reverse obstruction. Nat Med 2010;16:1299-304. DOI: https://doi.org/10.1038/nm.2237
Klimek L, Sperl A, Becker S, et al. Current therapeutical strategies for allergic rhinitis. Expert Opin Pharmacother 2019;20:83-9. DOI: https://doi.org/10.1080/14656566.2018.1543401
Bielory L, Lien KW, Bigelsen S. Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis. Drugs 2005;65:215-28. DOI: https://doi.org/10.2165/00003495-200565020-00004
Ekstedt S, Kumlien Georén S, Cardell LO. Effects of MP-AzeFlu enhanced by activation of bitter taste receptor TAS2R. Allergy Asthma Clin Immunol 2020;16:45. DOI: https://doi.org/10.1186/s13223-020-00438-w
Kemp JP, Meltzer EO, Orgel HA, et al. A dose-response study of the bronchodilator action of azelastine in asthma. J Allergy Clin Immunol 1987;79:893-9. DOI: https://doi.org/10.1016/0091-6749(87)90238-7
Albazzaz MK, Patel KR. Effect of azelastine on bronchoconstriction induced by histamine and leukotriene C4 in patients with extrinsic asthma. Thorax 1988;43:306-11. DOI: https://doi.org/10.1136/thx.43.4.306
Chervinsky P, Grossman J, Freitag JJ. Duration of action of a single dose of azelastine in patients with chronic asthma. J Asthma 1995;32:141-5. DOI: https://doi.org/10.3109/02770909509083235
An evaluation of the efficacy and safety of azelastine in patients with chronic asthma. Azelastine-Asthma Study Group. J Allergy Clin Immunol 1996;97:1218-24. DOI: https://doi.org/10.1016/S0091-6749(96)70188-4
Tinkelman DG, Bucholtz GA, Kemp JP, et al. Evaluation of the safety and efficacy of multiple doses of azelastine to adult patients with bronchial asthma over time. Am Rev Respir Dis 1990;141:569-74. DOI: https://doi.org/10.1164/ajrccm/141.3.569
Ollier S, Gould CA, Davies RJ. The effect of single and multiple dose therapy with azelastine on the immediate asthmatic response to allergen provocation testing. J Allergy Clin Immunol 1986;78:358-64. DOI: https://doi.org/10.1016/S0091-6749(86)80090-2
Rafferty P, Ng WH, Phillips G, et al. The inhibitory actions of azelastine hydrochloride on the early and late bronchoconstrictor responses to inhaled allergen in atopic asthma. J Allergy Clin Immunol 1989;84:649-57. DOI: https://doi.org/10.1016/0091-6749(89)90292-3
Rafferty P, Harrison PJ, Aurich R, et al. The in vivo potency and selectivity of azelastine as an H1 histamine-receptor antagonist in human airways and skin. J Allergy Clin Immunol 1988;82:1113-8. DOI: https://doi.org/10.1016/0091-6749(88)90151-0
Welsh EJ, Bara A, Barley E, et al. Caffeine for asthma. Cochrane Database Syst Rev 2010;2010:CD001112. DOI: https://doi.org/10.1002/14651858.CD001112.pub2
Shim JS, Ahn KM, Kim MH, et al. Lower baseline FEV1 is associated with greater FEV1 improvement after tiotropium add-on in uncontrolled asthma. Medicine 2025;104:e44912. DOI: https://doi.org/10.1097/MD.0000000000044912
Josephs LK, Gregg I, Mullee MA, et al. A longitudinal study of baseline FEV1 and bronchial responsiveness in patients with asthma. Eur Respir J 1992;5:32-9. DOI: https://doi.org/10.1183/09031936.93.05010032
Belvisi MG, Dale N, Birrell MA, et al. Bronchodilator activity of bitter tastants in human tissue. Nat Med 2011;17:776-8. DOI: https://doi.org/10.1038/nm0711-776b
Charous BL, Halpern EF, Steven GC. Hydroxychloroquine improves airflow and lowers circulating IgE levels in subjects with moderate symptomatic asthma. J Allergy Clin Immunol 1998;102:198-203. DOI: https://doi.org/10.1016/S0091-6749(98)70086-7
Cohen AB, Girard W, Mclarty J, et al. A controlled trial of colchicine to reduce the elastase load in the lungs of ex-cigarette smokers with chronic obstructive pulmonary disease. Am Rev Respir Dis 1991;143:1038-43. DOI: https://doi.org/10.1164/ajrccm/143.5_Pt_1.1038
Conaway Jr S, Huang W, Hernandez-Lara MA, et al. Molecular mechanism of bitter taste receptor agonist-mediated relaxation of airway smooth muscle. FASEB J 2024;38:e23842. DOI: https://doi.org/10.1096/fj.202400452R
Woo J-AA, Castaño M, Kee TR, et al. A Par3/LIM kinase/cofilin pathway mediates human airway smooth muscle relaxation by TAS2R14. Am J Respir Cell Mol Biol 2023;68:417. DOI: https://doi.org/10.1165/rcmb.2022-0303OC
Bachert C, Maspero J. Efficacy of second-generation antihistamines in patients with allergic rhinitis and comorbid asthma. J Asthma 2011;48:965-73. DOI: https://doi.org/10.3109/02770903.2011.616616
McTavish D, Sorkin EM. Azelastine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 1989;38:778-800. DOI: https://doi.org/10.2165/00003495-198938050-00005
Simons FER. Is antihistamine (H1‐receptor antagonist) therapy useful in clinical asthma? Clin Exp Allergy 1999;29:98-104. DOI: https://doi.org/10.1046/j.1365-2222.1999.0290s3098.x
Katayama S, Tsunoda H, Sakuma Y, et al. Effect of azelastine on the release and action of leukotriene C4 and D4. Int Arch Allergy Appl Immunol 1987;83:284-9.
An SS, Wang WCH, Koziol-White CJ, et al. TAS2R activation promotes airway smooth muscle relaxation despite β(2)-adrenergic receptor tachyphylaxis. Am J Physiol Lung Cell Mol Physiol 2012;303:L304-11. DOI: https://doi.org/10.1152/ajplung.00126.2012
Kamila T, Agnieszka K. An update on extra-oral bitter taste receptors. J Transl Med 2021;19:440. DOI: https://doi.org/10.1186/s12967-021-03067-y
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.